Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207083 | 0.70 | TRPA1 (0.39) | TRPA1 | |
| SCHEMBL208530 | 0.70 | TRPA1 (0.39) | TRPA1 | |
| SCHEMBL1386598 | 0.68 | TRPA1 (0.38) | TRPA1 | |
| SCHEMBL451436 | 0.60 | ABCG2 (0.35) | TRPA1 | |
| SCHEMBL6889575 | 0.60 | KDM4E (0.35) | TRPA1 | |
| SCHEMBL30184389 | 0.60 | TRPA1 (0.43) | TRPA1 | |
| SCHEMBL20499 | 0.60 | TRPA1 (0.43) | TRPA1 | |
| SCHEMBL1781023 | 0.60 | TRPA1 (0.43) | TRPA1 | |
| SCHEMBL113453 | 0.60 | KDM4E (0.35) | TRPA1 | |
| SCHEMBL2094585 | 0.59 | TRPA1 (0.42) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 376 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1021410-B1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER (US) | 2006-12-27 | — | — | EP | claimed |
| US-20030078261-A1 | Prostaglandin agonists | CAMERON KIMBERLY O (US) | 2003-04-24 | — | — | US | claimed |
| EP-1021410-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 2000-07-26 | — | — | EP | claimed |
| WO-1999019300-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 1999-04-22 | — | — | WO | claimed |
| US-11739131-B2 | Growth differentiation factor 15 (GDF-15) polypeptides | AMGEN INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11407721-B2 | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer | AMGEN INC. (US) | 2022-08-09 | — | — | US | disclosed |
| CN-113527512-A | Growth differentiation factor 15(GDF-15) constructs | 美国安进公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-105980400-B | Growth differentiation factor 15(GDF-15) constructs | 美国安进公司 | 2021-05-07 | — | — | CN | disclosed |
| US-20210079051-A1 | GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) CONSTRUCTS | AMGEN INC. (US) | 2021-03-18 | — | — | US | disclosed |
| US-10894814-B2 | Growth differentiation factor 15 (GDF-15) constructs | AMGEN INC. (US) | 2021-01-19 | — | — | US | disclosed |
| EP-3763734-A1 | GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) CONSTRUCTS | Amgen Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| CN-107531705-B | Bicyclic ketone sulfonamide compounds | 美国安进公司 | 2020-09-18 | — | — | CN | disclosed |
| WO-2000017165-A1 | 4-AMINO SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| EP-0987251-A1 | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as CETP inhibitors | Pfizer Products Inc. (US) | 2000-03-22 | — | — | EP | disclosed |
| EP-0946501-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999043663-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL] GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PRODUCTS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| EP-0911321-A2 | Compounds for the treatment of osteoporosis | PFIZER INC. (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1999019300-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 1999-04-22 | — | — | WO | disclosed |
| WO-1998058911-A2 | PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1998-12-30 | — | — | WO | disclosed |
| WO-1998028264-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894814-B2 | Growth differentiation factor 15 (GDF-15) constructs | IGFBP5, IGFBP2, IGFBP1 | TRPA1 4794/4885 |
| US-11407721-B2 | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer | MDM2, TP53, MDM4 | TRPA1 3515/4885 |
| US-11739131-B2 | Growth differentiation factor 15 (GDF-15) polypeptides | IGFBP5, IGFBP2, IGFBP1 | TRPA1 4740/4885 |
| US-20210079051-A1 | GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) CONSTRUCTS | IGFBP5, IGFBP2, IGFBP1 | TRPA1 4794/4885 |
| US-20030078261-A1 | Prostaglandin agonists | PTGER1, PTGER4, PTGIR | TRPA1 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.